Which generation of targeted drug is capmatinib?

Capmatinib (Capmatinib), this selective MET inhibitor carefully developed by Novartis, is specially designed to treat cancers caused by MET gene abnormalities. In the field of targeted drugs, capmatinib stands out as a second-generation MET inhibitor. Compared with first-generation products, it exhibits higher selectivity and excellent effectiveness.

As a representative of the second generation of MET inhibitors, capmatinib has a significant inhibitory effect on tumor cells with MET exon 14 skipping mutations. Its unique chemical structure optimization makes the drug highly selective when targeting the MET signaling pathway, and can accurately inhibit the abnormal activation of the MET gene, thereby effectively blocking the proliferation and metastasis pathways of tumor cells. At the same time, this generation of drugs has also made significant progress in reducing non-specific inhibition of other enzymes, reducing the incidence of adverse reactions and improving patient tolerance and overall efficacy.

Capmatinib's excellent efficacy in the treatment of patients with non-small cell lung cancer (NSCLC) carrying METexon14 skipping mutations has been fully verified. Clinical trial data show that the response rate of capmatinib is far higher than that of traditional therapies or first-generation MET inhibitors. Especially in the treatment-naïve patient group, its overall response rate (ORR) is as high as 68% , demonstrating its powerful anti-tumor activity.

For those patients with advanced or metastatic NSCLC who have METgene exon 14 skipping mutations, capmatinib is undoubtedly a boon. This mutation causes the overactivation of the MET protein and becomes an important driving force for tumor growth. Capmatinib precisely blocks METSignaling pathways provide new treatment options for such patients, especially for those patients who are ineffective or resistant to traditional treatments, and bring hope of life.

Looking to the future, with the continued advancement of targeted drug technology, capmatinib, as a second-generation MET inhibitor, will show broader potential in the treatment of non-small cell lung cancer. At the same time, in-depth research on other types of MET abnormalities is also expected to further broaden its application scope and bring the gospel of precision treatment to more cancer patients.

xa0

Reference materials

United StatesFDAOfficial website:https://www.fda.gov